Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIVE-U Sub-Study B: Vepdegestrant + Ribociclib in ER+/HER2- Advanced Breast Cancer
NCT05573555Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Mar 2023
- Primary completion
- Oct 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 4
01
Overview
A Phase 2 trial of vepdegestrant in breast cancer, sponsored by Pfizer. Started Mar 2023; status: terminated.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05573555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573555.